Amanta Healthcare Financial Results
- Market cap
- ₹806 crore
- P/E
- 54.9
- P/B
- 3.20
- ROE
- 16.4%
- Dividend yield
- 1.20%
For the year ended Mar 2023, Amanta Healthcare reported revenue of ₹258 crore and net profit of -₹2 crore, against ₹278 crore and ₹4 crore a year earlier.
Amanta Healthcare annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | 258 | 278 | 272 | 284 | 291 |
| Expenses | 204 | 220 | 212 | 224 | 232 |
| Operating profit | 53 | 58 | 60 | 60 | 60 |
| Operating margin % | 21% | 21% | 22% | 21% | 20% |
| Other income | 2 | -1 | 0 | 0 | 0 |
| Interest | 34 | 32 | 27 | 20 | 20 |
| Depreciation | 18 | 20 | 18 | 19 | 19 |
| Profit before tax | 3 | 5 | 15 | 21 | 21 |
| Tax % | 178% | 33% | 29% | 30% | 29% |
| Net profit | -2 | 4 | 11 | 15 | 15 |
| EPS (₹) | -0.54 | 0.94 | 2.70 | 3.83 | 3.78 |
| Dividend payout % | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Amanta Healthcare financial results — frequently asked questions
What is Amanta Healthcare's annual revenue and net profit?
For the financial year ended Mar 2023, Amanta Healthcare's revenue was ₹258 crore and net profit -₹2 crore; net profit fell 150.00% from ₹4 crore in Mar 2024.
How fast has Amanta Healthcare grown over three years?
From Mar 2026 to Mar 2023, Amanta Healthcare's revenue grew at a compound annual rate of -3.1%. Past growth does not indicate future results.
What is the EPS of Amanta Healthcare?
Annual EPS for Mar 2023 was -₹0.54.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Amanta Healthcare With ATS
Track AMANTA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.